Search

Displaying results 5961 - 5970 of 7058 in total
  1. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  2. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  3. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  4. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reupt...

  5. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … ICA-105665 is a novel small molecule compound for the treatment of epilepsy.

  6. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

  7. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

  9. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

  10. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.